Transplantation of xenogeneic islets: are we there yet?
Beta cell replacement therapy has been proposed as a novel therapy for the treatment of type 1 diabetes. The proof of concept has been demonstrated with successful islet allotransplantation. Islet xenotransplantation has been proposed as an alternative, more reliable, and infinite source of beta cells. The advantages of islet xenotransplantation are the ability to transplant a well differentiated cell that is responsive to glucose and the potential for genetic modification which focuses the treatment on the donor rather than the recipient. The major hurdle remains overcoming the severe cellular rejection that affects xenografts. This review will focus on the major advances that have occurred with genetic modification and the successful therapeutic strategies that have been demonstrated in nonhuman primates. Novel approaches to overcome cell-mediated rejection including biological agents that target selectively costimulation molecules, the development of local immunosuppression through genetic manipulation, and encapsulation will be discussed. Overall, there has been considerable progress in all these areas, which eventually should lead to clinical trials.
Centre for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, 2145, Australia, Philip.oconnell@swahs.health.nsw.gov.au.
Philip J
PJ
O'Connell
Peter J
PJ
Cowan
Wayne J
WJ
Hawthorne
Shounan
S
Yi
Andrew M
AM
Lew
D000818:Animals; D006084:Graft Rejection / Q000276:immunology; D064593:Heterografts / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D007249:Inflammation / Q000473:pathology; D016381:Islets of Langerhans Transplantation; D014183:Transplantation, Heterologous